Empagliflozin and left ventricular mass

Empagliflozin significantly reduced left ventricular mass over the course of 6 months in patients who have type 2 diabetes and with stable coronary artery disease. Also today, symptomatic hyperuricemia may respond to urate-lowering therapy, the risk for cancer in non-alcoholic fatty liver disease is 91% higher than the general population, the link between antibiotic use and obesity is insignificant at age 10.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify